Language

English

Publication Date

10-15-2025

Journal

The Journal of Infectious Diseases

DOI

10.1093/infdis/jiaf176

PMID

40298376

PMCID

PMC12526981

PubMedCentral® Posted Date

4-29-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Background: Mucosal immunity plays a critical role in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and replication. Understanding the capacity of coronavirus disease 2019 (COVID-19) vaccines to elicit both mucosal and systemic antibodies could help optimize vaccination strategies.

Methods: We conducted an open-label, phase 1/2 adaptive-design clinical trial to evaluate the safety and immunogenicity of COVID-19 immunizations. Healthy adults received 2 priming doses of mRNA-1273, a booster dose of mRNA-1273, and a second booster of bivalent (WA-1 and BA.4/BA.5) mRNA-1273.222. Adverse event data were collected. Serum and mucosal immunity were evaluated.

Results: One hundred six persons were enrolled. Thirty received all 4 study-related vaccine doses. All vaccines were well tolerated, with injection site pain, malaise, myalgias, and headache being the most frequently reported symptoms. Among those who received a second booster, 24 of 30 (80%) had serological evidence of SARS-CoV-2 infection. Following the second booster, increases in geometric mean binding and pseudovirus neutralization antibody titers to the ancestral strain and BA.1 and BA.5 variants were observed. Increases in mucosal immunoglobulin G and immunoglobulin A (IgA) antibodies in nasal and salivary samples were observed in both previously infected and infection-naive participants, although prior infection markedly boosted virus-specific mucosal IgA responses.

Conclusions: The mRNA-1273.222 booster vaccine was safe and immunogenic and induced mucosal antibody responses in previously infected and infection-naive persons.

Keywords

Humans, Male, Female, Adult, Antibodies, Viral, SARS-CoV-2, COVID-19, Immunization, Secondary, Middle Aged, COVID-19 Vaccines, Immunity, Mucosal, 2019-nCoV Vaccine mRNA-1273, Young Adult, Antibodies, Neutralizing, Adolescent, Immunoglobulin G, Immunoglobulin A, Antibody Formation, COVID-19, SARS-CoV-2, vaccine, booster, immunogenicity

Comments

Clinical trials registration: NCT04889209.

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.